author-photo

Kevin W. Song

University of British Columbia
Vancouver General Hospital

250

Papers

4765

Citations

Citation Trend

Filter By

Papers (177) Sort By

Journal Conference Others

P-120: Improving the risk stratification of multiple myeloma with a nucleotide editor/inflammation-based scoring system

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Autologous Stem Cell Transplant Outcome in Classic Hodgkin Lymphoma Patients in the Era of Post-Transplant Brentuximab Vedotin Consolidation

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Development of a new clinical index to easily assess frailty of elderly patients with multiple myeloma in Asian population.

2021 Scientific Reports
Show All
- Source
- Cite
- Save
Citations (0)
Mortality from multiple myeloma within one year following autologous stem cell transplantation: defining an ultra high-risk population

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
P-212: DREAMM-5 platform trial: Belantamab mafodotin (belamaf; GSK2857916) in combination with five different novel agents in patients with relapsed/refractory multiple myeloma (RRMM)

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Outcome of Relapsed and Refractory Peripheral T-Cell Lymphoma (PTCL) with Intention for Curative Therapy Incorporating High Dose Chemotherapy and Hematopoietic Stem Cell Transplant (HDC/SCT)

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.

2021 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (0)
Diffuse Large B-Cell Lymphoma (DLBCL) Patients with Late Relapses Who Are Transplant-Eligible Have Excellent Outcomes and May Represent Unique Biology

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.

2021 Future Oncology
Show All
- Source
- Cite
- Save
Citations (3)